Shock Synopsis July 2024

Margarita Elloso,Zachary Ricciuti,Marc G. Jeschke

DOI: https://doi.org/10.1097/shk.0000000000002411

2024-06-20

Shock

Abstract:COMPREHENSIVE THERAPEUTIC EFFICACY ANALYSIS OF INTRAVENOUS IMMUNOGLOBULIN IN TREATING SEPSIS-INDUCED COAGULOPATHY: A SINGLE-CENTER, RETROSPECTIVE OBSERVATIONAL STUDY

surgery,peripheral vascular disease,hematology,critical care medicine

What problem does this paper attempt to address?

Shock Synopsis December 2024

Basilia Zingarelli

DOI: https://doi.org/10.1097/shk.0000000000002524

2024-12-03

Shock

Abstract:NOVEL ACTIVE PROTEINS FOR SEPSIS PROGNOSIS REVEALED THROUGH SCRNA-SEQ AND QUANTITATIVE PROTEOMICS Liu et al. (pp. 738–745) adopted multiomics analysis to identify novel biomarkers of sepsis. The authors compared differences in gene expression by single-cell RNA sequencing, protein activity inference by Viper algorithm, and protein expression by data-independent acquisition proteomic analysis in survivor and non-survivor patients with sepsis and in posttraumatic patients included as control cohort. The authors identified three proteins (SPI1, MEF2A, and UBTF) with a positive correlation with survival in septic patients. On the contrary, the authors found that elevated expression of CBX3 had a negative correlation with sepsis outcomes. Gene set variation enrichment analysis revealed that negative outcomes of sepsis were associated with alterations in cellular apoptosis and inflammatory pathways.

surgery,peripheral vascular disease,hematology,critical care medicine
Shock Synopsis April 2024

Diana Tedesco,Fadi Khalaf,Marc G. Jeschke

DOI: https://doi.org/10.1097/shk.0000000000002368

2024-04-13

Shock

Abstract:ROLE OF MICROGLIA IN SEPSIS-ASSOCIATED ENCEPHALOPATHY PATHOGENESIS: AN UPDATE Sepsis-associated encephalopathy (SAE) is a severe complication of sepsis characterized by cognitive dysfunction and high mortality rates. Yu et al. review how microglia, the main macrophage in the CNS, play a crucial role in SAE by inducing neuroinflammation, brain tissue injury, and neuronal dysregulation through various pathways. As part of the review, they discuss how targeting microglia could be a potential therapeutic strategy for ameliorating SAE by addressing neuroinflammation and other underlying mechanisms.

surgery,peripheral vascular disease,hematology,critical care medicine
Shock Synopsis June 2024

DOI: https://doi.org/10.1097/shk.0000000000002393

2024-05-25

Shock

Abstract:RESEARCH PROGRESS OF CURCUMIN IN THE TREATMENT OF SEPSIS Sepsis is a life-threatening infectious disease and its pathogenesis is still incompletely understood. Curcumin has anti-inflammatory effects and might be efficient in sepsis therapy. Tao et al. (pp. 805–816) summarize the current knowledge on the use of Curcumin in sepsis therapy.

surgery,peripheral vascular disease,hematology,critical care medicine
The Clinical Efficacy of Intravenous IgM-enriched Immunoglobulin (pentaglobin) in Sepsis or Septic Shock: a Meta-Analysis with Trial Sequential Analysis

Jie Cui,Xuxia Wei,Haijin Lv,Yuntao Li,Ping Li,Zhen Chen,Genglong Liu

DOI: https://doi.org/10.1186/s13613-019-0501-3

IF: 10.318

2019-01-01

Annals of Intensive Care

Abstract:Sepsis is characterized by a complex immune response. This meta-analysis evaluated the clinical effectiveness of intravenous IgM-enriched immunoglobulin (IVIgGM) in patients with sepsis and septic shock. Four databases, PubMed, the Cochrane Library, the ISI Web of Knowledge, and Embase, were systematically searched from inception to June 2018 to update the 2013 edition of the Cochrane review by two investigators, who independently selected studies, extracted relevant data, and evaluated study quality. Data were subjected to a meta-analysis and trial sequential analysis (TSA) for the primary and secondary outcomes. Level of evidence was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) scale. Nineteen studies comprising 1530 patients were included in this meta-analysis. Pooled analyses showed that the use of IVIgGM reduced the mortality risk of septic patients (relative risk 0.60; 95% confidence interval [CI] 0.52–0.69, I2 = 0%). TSA showed that IVIgGM had a significant effect on mortality. Additionally, the meta-analysis suggested that use of IVIgGM shortened length of mechanical ventilation (mean difference − 3.16 days; 95% CI − 5.71 to − 0.61 days) and did not shorten length of stay in the intensive care unit (mean difference − 0.38 days; 95% CI − 3.55 to 2.80 days). The GRADE scale showed that the certainty of the body of evidence was low for both benefits and IVIgGM. Administration of IVIgGM to adult septic patients may be associated with reduced mortality. Treatment effects tended to be smaller or less consistent when including only those studies deemed adequate for each indicator. The available evidence is not clearly sufficient to support the widespread use of IVIgGM in the treatment of sepsis. Trial registration PROSPERO registration number: CRD42018084120. Registered on 11 February 2018.
Comprehensive Therapeutic Efficacy Analysis of Intravenous Immunoglobulin in Treating Sepsis-induced Coagulopathy: A Single-Center, Retrospective Observational Study

Jingyun Fang,Peng Huang,Wanfu Cui,Ye Lin,Dan Rong,Xu Li

DOI: https://doi.org/10.1097/shk.0000000000002336

2024-02-07

Shock

Abstract:Abstract OBJECTIVES To investigate the efficacy of intravenous immunoglobulin (IVIg) in treating sepsis-induced coagulopathy (SIC). Methods A retrospective controlled analysis was conducted on 230 patients with SIC at Ganzhou People's Hospital from January 2016 to December 2022. All patients were screened using propensity score matching and treated according to the SSC2016 guidelines. Compared to the control group (n = 115), patients in the test group (n = 115) received IVIg (200 mg/kg.d) for 3 consecutive days post-admission. The rating scales, coagulation function, survival, and treatment duration were evaluated. Results On day 3 of treatment, both groups exhibited reduced PLT and TEG-MA levels, with the control group showing a more significant decrease ( P < 0.05). By the 5th day, these levels had recovered in both groups. However, the test group experienced a significant increase by day 7 ( P < 0.05). Coagulation factors II and X began to increase on day 3, and normalization was significantly faster in the test group on day 5 ( P < 0.05). The levels of PT, INR, APTT, D-dimer, FIB, FDP, TEG-R, and TEG-K exhibited a notable decline on day 3 and demonstrated significantly faster recovery on day 5 in the test group ( P < 0.05). Additionally, both groups showed a reduction in APACHE II, SOFA, DIC, and LAC levels on day 3, but the test group’s scores decreased significantly more by day 7 ( P < 0.05). Within the test group, WBC count, CRP, PCT, IL-6, and Tmax levels were lower ( P < 0.05). Furthermore, the test group demonstrated shorter duration for ICU stay, mechanical ventilation, and CRRT ( P < 0.05). No significant differences were observed in the duration of fever or vasoactive drug use between the groups. However, the log-rank method indicated a higher 28-day survival rate in the test group ( P < 0.05). Conclusion IVIg can successfully increase platelet count and coagulation factors, correct coagulation disorders, enhance organ function, and reduce 28-day mortality in patients with SIC.

surgery,peripheral vascular disease,hematology,critical care medicine
Recombinant Human Activated Protein C for the Treatment of Severe Sepsis and Septic Shock: a Study Protocol for Incorporating Observational Evidence Using a Bayesian Approach.

Zhongheng Zhang

DOI: https://doi.org/10.1136/bmjopen-2014-005622

IF: 3.006

2014-01-01

BMJ Open

Abstract:INTRODUCTION:Activated protein C (aPC) plays a pivotal role in modulating a severe inflammatory response and is thought to be beneficial for patients with sepsis. However, several meta-analyses of randomised controlled trials (RCTs) show that aPC is not significantly associated with improved survival in critically ill patients with sepsis. One suggestion is that these analyses simply ignored observational evidence. The present study aims to quantitatively demonstrate how observational data can alter the findings derived from synthesised evidence from RCTs by using a Bayesian approach.METHODS AND ANALYSIS:RCTs and observational studies investigating the effect of aPC on mortality outcome in critically ill patients with sepsis will be included. The quality of included RCTs will be assessed by using the Delphi list. Publication bias will be quantitatively analysed by using the traditional Egger regression test and the Begg rank correlation test. Observational data will be used as the informative prior for the distribution of OR. A power transformation of the observational data likelihood will be considered. Observational evidence will be down-weighted by a power of α which takes values from 0 to 1. Trial sequential analysis will be performed to quantify the reliability of data in meta-analysis adjusting significance levels for sparse data and multiple testing on accumulating trials.TRIAL REGISTRATION NUMBER:PROSPERO (CRD42014009562).
Dosing of Extracorporeal Cytokine Removal In Septic Shock (DECRISS): protocol of a prospective, randomised, adaptive, multicentre clinical trial

Anna Kanjo,Zsolt Molnar,Noémi Zádori,Noémi Gede,Bálint Erőss,Lajos Szakó,Tamás Kiss,Zsolt Márton,Manu L N G Malbrain,Konstanty Szuldrzynski,Jakub Szrama,Krzysztof Kusza,Klaus Kogelmann,Péter Hegyi

DOI: https://doi.org/10.1136/bmjopen-2021-050464

IF: 3.006

2021-08-26

BMJ Open

Abstract:Introduction: Sepsis and septic shock have mortality rates between 20% and 50%. In sepsis, the immune response becomes dysregulated, which leads to an imbalance between proinflammatory and anti-inflammatory mediators. When standard therapeutic measures fail to improve patients' condition, additional therapeutic alternatives are applied to reduce morbidity and mortality. One of the most recent alternatives is extracorporeal cytokine adsorption with a device called CytoSorb. This study aims to compare the efficacy of standard medical therapy and continuous extracorporeal cytokine removal with CytoSorb therapy in patients with early refractory septic shock. Furthermore, we compare the dosing of CytoSorb adsorber device changed every 12 or 24 hours. Methods and analysis: It is a prospective, randomised, controlled, open-label, international, multicentre, phase III study. Patients fulfilling the inclusion criteria will be randomly assigned to receive standard medical therapy (group A) or-in addition to standard treatment-CytoSorb therapy. CytoSorb treatment will be continuous and last for at least 24 hours, CytoSorb adsorber device will be changed every 12 (group B) or 24 hours (group C). Our primary outcome is shock reversal (no further need or a reduced (≤10% of the maximum dose) vasopressor requirement for 3 hours) and time to shock reversal (number of hours elapsed from the start of the treatment to shock reversal).Based on sample size calculation, 135 patients (1:1:1) will need to be enrolled in the study. A predefined interim analysis will be performed after reaching 50% of the planned sample size, therefore, the corrected level of significance (p value) will be 0.0294. Ethics and dissemination: Ethics approval was obtained from the Scientific and Research Ethics Committee of the Hungarian Medical Research Council (OGYÉI/65049/2020). Results will be submitted for publication in a peer-reviewed journal. Trial registration number: NCT04742764; Pre-results.
Efficacy and safety of corticosteroids for septic shock in immunocompromised patients: A cohort study from MIMIC

Xin Lu,Xue Wang,Yanxia Gao,Shiyuan Yu,Lina Zhao,Zhongheng Zhang,Huadong Zhu,Yi Li

DOI: https://doi.org/10.1016/j.ajem.2020.02.002

IF: 3.6

2021-01-01

The American Journal of Emergency Medicine

Abstract:Background: Corticosteroids have been widely used as adjunct therapy for septic shock for many decades, but both the efficacy and safety remain unclear. The study was designed to investigate overall benefits and potential risks of corticosteroids in immunocompromised patients with septic shock.Methods: The Medical Information Mart for Intensive Care III (MIMIC-III) database was employed to conduct a cohort study. Immunocompromised patients with septic shock were enrolled and categorized by whether exposure to intravenous corticosteroids. Cox Proportional-Hazards models were used to control for confounders and assess the relationship between corticosteroids use and mortality.Results: A total of 866 patients were enrolled in this study, including 395 in the corticosteroids group and 471 in the non-corticosteroids group. Corticosteroids infusion was not associated with improved 30-day mortality in overall immunocompromised population [34.7% vs 32.1%; adjusted hazard ratio (HR) 1.11, 95% confidence interval (CI) 0.87-1.43, p = 0.37]. The mortality effects were similar in 90-day, 180-day, 1-year and hospital mortality. For the subgroup of patients with metastatic cancer, corticosteroids infusion was associated with a statistically significant increase in the 30-day mortality risk (HR 1.58, 95% CI 1.06-2.37; p = 0.02). Corticosteroids had adverse effects on hemodynamic stability, prolonged ICU and hospital duration, and increased risk of hyperglycemia.Conclusions: Corticosteroids therapy for the maintenance of blood pressure was not associated with improved mortality or hemodynamic stability in overall immunocompromised population with septic shock. Future randomized clinical trials are required to validate the effects of corticosteroids for septic shock in the special immunocompromised population.(c) 2020 Elsevier Inc. All rights reserved.
Immunometabolic Chaos in Septic Shock

Deepmala Shrestha,Bishnu Pant,Sanjoy Roychowdhury,Anugraha Gandhirajan,Emily Cross,Mamta Chhabria,Seth Bauer,Margaret Jeng,Megan Mitchell,Omar Mehkri,Fatima Zaidi,Akash Ahuja,Xiaofeng Wang,Yuxin Wang,Christine McDonald,Michelle Longworth,Thaddeus Stappenbeck,George R Stark,Rachel Scheraga,Vidula Vachharajani

DOI: https://doi.org/10.1093/jleuko/qiae211

2024-09-28

Abstract:Septic shock is associated with over 40% mortality. The immune response in septic shock is tightly regulated by cellular metabolism and transitions from early hyper-inflammation to later hypo-inflammation. Patients are susceptible to secondary infections during hypo-inflammation. The magnitude of the metabolic dysregulation and the effect of plasma metabolites on the circulating immune cells in septic shock are not reported. We hypothesized that the accumulated plasma metabolites affect the immune response in septic shock during hypo-inflammation. Our study took a unique approach. Using peripheral blood from adult septic shock patients and healthy controls, we studied: 1. Whole blood stimulation ± E. Coli lipopolysaccharide (LPS: endotoxin) to analyze plasma TNF protein, and 2. Plasma metabolomic profile by Metabolon. Inc. 3. We exposed peripheral blood mononuclear cells (PBMCs) from healthy controls to commercially available carbohydrate, amino acid, and fatty acid metabolites and studied the response to LPS. We report that: 1. The whole blood stimulation of the healthy control group showed a significantly upregulated TNF protein, while the septic shock group remained endotoxin tolerant, a biomarker for hypo-inflammation. 2. A significant accumulation of carbohydrate, amino acid, fatty acid, ceramide, sphingomyelin, and TCA cycle pathway metabolites in septic shock plasma. 3. In vitro exposure to five metabolites repressed while two metabolites upregulated the inflammatory response of PBMCs to LPS. We conclude that the endotoxin-tolerant phenotype of septic shock is associated with a simultaneous accumulation of plasma metabolites from multiple metabolic pathways, and these metabolites fundamentally influence the immune response profile of circulating cells.
Intravenous Immunoglobulin G Therapy in Streptococcal Toxic Shock Syndrome: A European Randomized, Double-Blind, Placebo-Controlled Trial

Jessica Darenberg,Nahla Ihendyane,Jan Sjölin,Ewa Aufwerber,Sven Haidl,Per Follin,Jan Andersson,Anna Norrby-Teglund,J. Darenberg,N. Ihendyane,J. Sjolin,E. Aufwerber,S. Haidl,P. Follin,J. Andersson,A. Norrby-Teglund,

DOI: https://doi.org/10.1086/376630

IF: 20.999

2003-08-01

Clinical Infectious Diseases

Abstract:The efficacy and safety of high-dose intravenous polyspecific immunoglobulin G (IVIG) as adjunctive therapy in streptococcal toxic shock syndrome (STSS) were evaluated in a multicenter, randomized, double-blind, placebo-controlled trial. The trial was prematurely terminated because of slow patient recruitment, and results were obtained from 21 enrolled patients (10 IVIG recipients and 11 placebo recipients). The primary end point was mortality at 28 days, and a 3.6-fold higher mortality rate was found in the placebo group. A significant decrease in the sepsis-related organ failure assessment score at days 2 (P=.02) and 3 (P=.04) was noted in the IVIG group. Furthermore, a significant increase in plasma neutralizing activity against superantigens expressed by autologous isolates was noted in the IVIG group after treatment (P=.03). Although statistical significance was not reached in the primary end point, the trial provides further support for IVIG as an efficacious adjunctive therapy in STSS.

immunology,infectious diseases,microbiology
Shock Synopsis March 2024

DOI: https://doi.org/10.1097/shk.0000000000002346

2024-03-31

Shock

Abstract:DERIVATION OF A MORTALITY PREDICTION MODEL IN CRITICAL CARE PATIENTS WITH CIRRHOSIS AND SEPSIS Many septic patients have significant comorbidities which complicate diagnostic algorithms predicting mortality. Cirrhosis is one of these comorbidities and a paper by de Moraes et al. (pp. 382-386) developed a mortality prediction model based on over 2000 patients admitted with cirrhosis. Of these patients 277 developed sepsis with a 37% in hospital mortality. Multiple clinical and laboratory parameters were used to predict mortality.

surgery,peripheral vascular disease,hematology,critical care medicine
What's New in Shock, May 2019?

Rachel M Russo,Hasan B Alam,Hasan B. Rachel M.; Alam Russo

DOI: https://doi.org/10.1097/SHK.0000000000001322

2019-10-07

Shock

Abstract:This issue of Shock provides another excellent selection of 16 manuscripts spanning the basic sciences and clinical outcomes of shock, injury, inflammation, and sepsis. An important theme this month is organ dysfunction in sepsis. Neutrophil dysregulation is a critical step early in the development of septic organ dysfunction. Soroush et al. (1) previously identified protein kinase C-delta (PKC-∂) as a key regulator of neutrophil activation and now searched for a site-specific target for future anti-inflammatory therapies. They demonstrated that PKC-∂ tyrosine 155 is a key phosphorylation site involved in PKC-∂'s regulation of neutrophil activation and migration. These studies provide mechanistic insight into the regulation of inflammation and earned the authors the new investigator award. Future studies will be aimed at identifying novel targets for treating inflammation. Continuing on the theme of neutrophil dysregulation in sepsis, Jin et al. (2) investigated extracellular cold-inducible RNA-binding protein (CIRP) related acute lung injury in a murine model of septic shock. They found CIRP stimulates neutrophil reverse transendothelial migration and increase local pulmonary inflammation in a dose-dependent fashion. Yu et al. (3) also studied inflammatory mediators of acute lung injury in sepsis. They examined the role of NLRP3 inflammasomes and NF-kB signaling proteins in a mouse model of severe acute pancreatitis. They found surfactant protein D exerts protective effects against acute lung injury by suppressing NLRP3 inflammasome and NF-kB. Future studies will be required to determine if any of these pathways may be exploited to reduce inflammation and acute lung injury. Altered mitochondrial respiration comprises another early feature of organ dysfunction in sepsis. Jang et al. (4) used plasma derived bone marrow cells to evaluate mitochondrial respiration in patients with sepsis, compared with normal controls of various ages. They found a reduction in mitochondrial ATP production in sepsis that may signify impaired oxygen delivery or utilization in end organs, which could be detected and trended using this serum marker. The ability to measure mitochondrial respiration with a blood test represents a growing area of research into minimally invasive means of assessing cellular function to predict sepsis severity and prognosis. Key to cellular function is microcirculatory function, the loss of which is a harbinger of poor prognosis in sepsis. Côrtes et al. (5) assessed microvascular function in sepsis using the perfusion index after transient arterial occlusion. The authors anticipated a larger delta would correlate with higher microvascular reserve, indicating less dysfunction and a better prognosis. However, they found a larger delta correlated with greater reactive hyperemia, increased serum lactate levels, and worse mortality. Vallée et al. (6) also used the perfusion index to assess microvascular dysfunction for predicting sepsis severity. The authors tested cutaneous capnography and perfusion index coupled with intermittent dynamic heating of the ear lobe to assess cutaneous vasoreactivity. This method was able to diagnose septic shock apart from cardiogenic shock, hemorrhage shock, and nonshock states, and predict mortality with high sensitivity and specificity. This study adds to a growing a body of literature demonstrating a link between microvascular vasoreactivity and prognosis in septic shock. Although we search for new ways to predict outcomes and improve survival, early implementation of resuscitative measures, including antibiotics, has long been established as fundamental for improving survival from sepsis. Yu et al. (7) postulated the Emergency Department (ED) may have greater resources to allow for appropriate implementation of these time-critical therapies. To validate the findings of a previously published study from the United States, Yu et al. conducted a retrospective analysis of patients in Taiwan admitted with sepsis. They confirmed lower in-hospital and 90-day mortality in those admitted through the ED to those directly admitted. Future studies are needed to determine if this finding is in fact related to the timing of diagnosis and treatment. One time-sensitive intervention that is frequently required for resuscitation and management of patients in septic shock is placement of a central venous catheter. Point of care ultrasound is commonly used for central lines placed by Emergency Medicine physicians and Intensivists. Ablordeppey et al. (8) conducted a survey of these providers to determine how often point of care ultrasound is being used to confirm the position of central ven -Abstract Truncated-

surgery,peripheral vascular disease,hematology,critical care medicine
High-dose intravenous immunoglobulin versus albumin 4% in paediatric toxic shock syndrome: a randomised controlled feasibility study

Aurélie Portefaix,Carole Dhelens,Morgan Recher,Fleur Cour-Andlauer,Jérôme Naudin,Guillaume Mortamet,Nicolas Joram,Pierre Tissières,Tiphanie Ginhoux,Behrouz Kassai,Florent Boutitie,Delphine Maucort-Boulch,Etienne Javouhey

DOI: https://doi.org/10.1136/archdischild-2022-325274

2024-02-15

Archives of Disease in Childhood

Abstract:Purpose Toxic shock syndrome (TSS) is a rare disease responsible for significant morbidity and mortality. Intravenous immunoglobulin (IG) therapy in paediatric TSS could improve shock and organ failure, but more consistent efficacy and safety data are needed. Our objective was to determine whether a randomised clinical trial (RCT) assessing intravenous IG in TSS in children is feasible. Methods We performed a multicentre, feasibility, double-blind RCT assessing efficacy of high-dose intravenous IG versus albumin 4% (control group) within the first 12 hours of shock onset. Included patients were aged above 1 month and below 18 years with suspected TSS and septic shock. Feasibility was assessed by measuring inclusion rate, protocol compliance and missing data regarding death and the Pediatric Logistic Organ Dysfunction-2 (PELOD-2) Score. Other secondary clinical outcomes were evaluated during hospital stay, at 60 day and 1 year. Results 28 patients, admitted in 6 paediatric intensive care units during 36 consecutive months and followed for 1 year, received the allocated treatment: 13 in intravenous IG group, 15 in control group. The median age was 10.6 years and the sex ratio was 1. Inclusion rate was above 50%, protocol deviations were below 30% and missing data regarding death and PELOD-2 Score below 10%. No difference concerning secondary clinical outcomes between groups was observed, and more adverse events were reported in the control group. Conclusion It seems to be feasible to conduct an RCT assessing intravenous IG efficacy and safety in paediatric TSS but must be realised internationally, with choice of a clinically relevant endpoint and a specific design in order to be realistic. Trial registration number NCT02219165 .

pediatrics
Cellular Immunotherapy for Septic Shock. A Phase I Clinical Trial

Lauralyn A. McIntyre,Duncan J. Stewart,Shirley H. J. Mei,David Courtman,Irene Watpool,John Granton,John Marshall,Claudia dos Santos,Keith R. Walley,Brent W. Winston,Kenny Schlosser,Dean A. Fergusson

DOI: https://doi.org/10.1164/rccm.201705-1006oc

IF: 24.7

2018-02-01

American Journal of Respiratory and Critical Care Medicine

Abstract:RATIONALE: In septic animal models mesenchymal stem (stromal) cells (MSCs) modulate inflammation, enhance tissue repair and pathogen clearance, and reduce death.OBJECTIVES: To conduct a phase I dose escalation trial of MSCs in septic shock with the primary objective of examining the safety and tolerability of MSCs.METHODS: We enrolled nine participants within 24 hours of admission to the ICU. A control cohort of 21 participants was enrolled before starting the MSC interventional cohort to characterize expected adverse events (AEs) and to serve as a comparator for the intervention cohort. Three separate MSC dose cohorts, with three participants per cohort, received a single intravenous dose of 0.3, 1.0, and 3.0 × 10<sup>6</sup> cells/kg. A prespecified safety plan monitored participants for the occurrence of AEs; cytokines were collected at prespecified time points.MEASUREMENTS AND MAIN RESULTS: Ages of participants in the interventional versus observational cohorts were median of 71 (range, 38-91) and 61 (range, 23-95). Acute Physiology and Chronic Health Evaluation scores were median of 25 (range, 11-28) and 26 (range, 17-32). MSC doses ranged from 19 to 250 million cells. There were no prespecified MSC infusion-associated or serious unexpected AEs, nor any safety or efficacy signals for the expected AEs or the measured cytokines between the interventional and observational cohorts.CONCLUSIONS: The infusion of freshly cultured allogenic bone marrow-derived MSCs, up to a dose of 3 million cells/kg (250 million cells), into participants with septic shock seems safe. Clinical trial registered with www.clinicaltrials.gov (NCT02421484).

respiratory system,critical care medicine
Protocol for a pilot randomized controlled trial comparing plasma with balanced crystalloid resuscitation in surgical and trauma patients with septic shock

Shuyan Wei,Lillian S Kao,Henry E Wang,Ronald Chang,Jeanette Podbielski,John B Holcomb,Charles E Wade

DOI: https://doi.org/10.1136/tsaco-2018-000220

2018-09-01

Abstract:Background Septic shock is a public health problem with high mortality. There remains a knowledge gap regarding the optimal resuscitation fluid to improve clinical outcomes, and the underlying mechanism by which fluids exert their effect. Shock-induced endotheliopathy (SHINE) is thought to be a shared pathophysiologic mechanism associated with worsened outcomes in critically ill trauma and sepsis patients. SHINE is characterized by breakdown of the glycocalyx—a network of membrane-bound proteoglycans and glycoproteins that covers the endothelium. This has been associated with capillary leakage and microvascular thrombosis, organ dysfunction, and mortality. Biomarkers of SHINE have been shown to correlate with clinical outcomes in patients with septic shock. Interventions to mitigate SHINE may improve outcomes in patients with septic shock. In surgical/trauma patients with septic shock, initial plasma resuscitation as compared with balanced crystalloid (BC) resuscitation will mitigate biomarkers of SHINE and improve clinical outcomes. Methods A pilot, single-center randomized controlled trial (RCT) will compare initial plasma to BC resuscitation in surgical and trauma patients with septic shock. Patients will be enrolled based on a Sepsis Screening Score of ≥4 with a suspected source of infection. Patient randomization only occurs if they meet the criteria: (1) hypotension with mean arterial pressure 4 mmol/L, altered mental status or decreased urine output of <0.5 mL/kg in the past hour. Results The primary outcome is a reduction in serum biomarkers at 6 hours. Secondary outcomes will include clinical outcomes such as intensive care unit-free days, organ dysfunction, and in-hospital mortality. Discussion This trial will provide insights into the effects of initial plasma resuscitation on SHINE. Furthermore, it will provide unbiased estimates regarding the feasibility, safety, and clinical efficacy of plasma resuscitation in septic shock on which to base subsequent adequately powered multicenter RCTs. Trail registration number ClinicalTrials.gov ( NCT03366220 ).
Shadows and lights in sepsis immunotherapy

Guillaume Monneret,Muzhda Haem Rahimi,Anne-Claire Lukaszewicz,Fabienne Venet,Morgane Gossez

DOI: https://doi.org/10.1080/14656566.2024.2418987

Abstract:Introduction: Sepsis remains a major global public health challenge. The host's response in sepsis involves both an exaggerated inflammatory reaction and immunosuppressive mechanisms. A better understanding of this response has shed light on the failure of anti-inflammatory therapies administered under the 'one size fits all' approach during the last decades. Areas covered: To date, patients' management has moved toward a comprehensive precision medicine approach that aims to personalize immunotherapy, whether anti-inflammatory or immunostimulatory. Large Prospective interventional randomized controlled trials validating this approach are about to start. A crucial prerequisite for these studies is to stratify patients based on biomarkers that will help defining the patients' immuno-inflammatory trajectory. Expert opinion: Some biomarkers are already available in routine clinical care, while improvements are anticipated through the standardized use of transcriptomics and other multi-omics technologies in this field. With these precautions in mind, it is reasonable to anticipate improvement in outcomes in sepsis.
The Effect of Sepsis and Septic Shock on the Viscoelastic Properties of Clot Quality and Mass Using Thromboelastometry: A Prospective Observational Study

Priyanka Mohapatra,Arvind Kumar,Rakesh Kumar Singh,Ruchi Gupta,Mumtaz Hussain,Swati Singh,Pankaj Kumar

DOI: https://doi.org/10.5005/jp-journals-10071-24539

Abstract:Background: Sepsis is associated with wide variable coagulation abnormalities. Thromboelastography (TEG) effectively measures the viscoelastic properties of the clots. This study aims to illustrate the viscoelastic properties of clot quality and mass in sepsis and septic shock patients using TEG, as an effective tool over standard coagulation tests. Materials and methods: A single-center, prospective observational study was conducted. 50 patients each meeting the criteria for sepsis and septic shock, and a healthy group of 30 patients was included in the study. Blood samples were obtained and analyzed for standard coagulation tests, platelet count, fibrinogen, and TEG study. Results: A total of 130 patients were included. Septic shock patients had a higher sequential (sepsis-related) organ failure score. Prothrombin time (PT) and activated partial thromboplastin time (aPTT) were increased significantly as compared to the sepsis and control groups. TEG markers such as alpha angle, and maximum amplitude (MA) were significantly prolonged while reaction time (R time), was significantly shortened in the sepsis group as compared to the healthy group, suggestive of a hypercoagulable state in sepsis patients. While in septic shock patients, MA and Lysis Index 30 (LY 30) were significantly prolonged and, R time was significantly shortened compared to all other groups. Even though LY30 in sepsis patients was found to be within the normal range (p < 0.001), 18% of patients had prolonged LY30 indicating a hypercoagulable state with impaired fibrinolysis. Conclusion: Thromboelastography, as a point-of-care test combined with conventional coagulation tests can provide additional, clinically relevant information on coagulopathy, and outcome, and thus help guide treatment modality in sepsis and septic shock-induced coagulopathy. How to cite this article: Mohapatra P, Kumar A, Singh RK, Gupta R, Hussain M, Singh S, et al. The Effect of Sepsis and Septic Shock on the Viscoelastic Properties of Clot Quality and Mass Using Thromboelastometry: A Prospective Observational Study. Indian J Crit Care Med 2023;27(9):625-634.
Evaluation of the Efficacy and Safety of Intravenous Immunoglobulin (IVIG) in Moderate-to-Severe Hospitalized COVID-19 Patients: A Randomized, Open-Label Parallel-Group Study

Sachin Gautam,Govind Mawari,Mradul Kumar Daga,Naresh Kumar,Harpreet Singh,Sandeep Garg,Suresh Kumar,Monika Gajendrakumar,Mahak Golani,Ishan Rohatgi,Sayan Sarkar,Shubham Kaushik,Manish Kumar Jha,Sweety Mehra

DOI: https://doi.org/10.1155/2024/7209380

2024-05-22

Canadian Journal of Infectious Diseases and Medical Microbiology

Abstract:Purpose. Since February 2020, the world has been overwhelmed by the SARS-CoV-2 outbreak, and several patients suffered interstitial pneumonia and respiratory failure requiring mechanical ventilation, threatening the capability of healthcare systems to handle this amount of critical cases. Intravenous immunoglobulins (IVIG) possess potential immunomodulatory properties beneficial for COVID-19 patients, yet evidence supporting IVIG as adjunctive therapy remains sparse. This study evaluated the outcomes of adjunctive IVIG with the standard of care (SoC) in moderate-to-severe COVID-19 patients. Methods. This randomized study included 59 moderate-to-severe COVID-19 patients with known comorbidities. One arm (n = 33) received high-dose IVIG (400 mg/kg/day) within 48 hours for five days alongside SoC, while the other arm (n = 26) received SoC, comprising steroids, enoxaparin, and remdesivir. The primary endpoint was clinical improvement, as measured by the National Early Warning Score 2 (NEWS2) and discharged/death proportions. Secondary outcomes included IVIG safety, hospitalization duration, changes in oxygen saturation, inflammatory markers, IgG titer, CTSS (CT severity score), and radiological findings. Results. There was an improvement in the NEWS2 at the end of treatment in the IVIG arm (5.67 vs. 5.96). A significant absolute effect improvement (Day 1 vs. Day 9) was seen in serum LDH, D-dimer, hs-CRP, IL-6, CTSS, procalcitonin, respiratory rate, and chest radiographic findings. SARS-CoV-2 IgG titer increased significantly in the IVIG arm. There was a statistically significant reduction in mortality in the IVIG group (5 vs. 10). Conclusion. IVIG was a safe and effective adjunctive therapy to SoC treatment in moderate-to-severe COVID-19 patients needing ventilatory support. Furthermore, studies are required to validate our findings. This trial is registered with CTRI/2021/05/033622.

infectious diseases,microbiology
Characterization of Early Peripheral Immune Responses in Patients with Sepsis and Septic Shock

Jesús Beltrán-García,Rebeca Osca-Verdegal,Beatriz Jávega,Guadalupe Herrera,José-Enrique O’Connor,Eva García-López,Germán Casabó-Vallés,María Rodriguez-Gimillo,José Ferreres,Nieves Carbonell,Federico V. Pallardó,José Luis García-Giménez

DOI: https://doi.org/10.3390/biomedicines10030525

IF: 4.757

2022-02-23

Biomedicines

Abstract:(1) Background: Sepsis is a life-threatening condition caused by an abnormal host response to infection that produces altered physiological responses causing tissue damage and can result in organ dysfunction and, in some cases, death. Although sepsis is characterized by a malfunction of the immune system leading to an altered immune response and immunosuppression, the high complexity of the pathophysiology of sepsis requires further investigation to characterize the immune response in sepsis and septic shock. (2) Methods: This study analyzes the immune-related responses occurring during the early stages of sepsis by comparing the amounts of cytokines, immune modulators and other endothelial mediators of a control group and three types of severe patients: critically ill non-septic patients, septic and septic shock patients. (3) Results: We showed that in the early stages of sepsis the innate immune system attempts to counteract infection, probably via neutrophils. Conversely, the adaptive immune system is not yet fully activated, either in septic or in septic shock patients. In addition, immunosuppressive responses and pro-coagulation signals are active in patients with septic shock. (4) Conclusions: The highest levels of IL-6 and pyroptosis-related cytokines (IL-18 and IL-1α) were found in septic shock patients, which correlated with D-dimer. Moreover, endothelial function may be affected as shown by the overexpression of adhesion molecules such as s-ICAM1 and E-Selectin during septic shock.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
A Biomimetic Membrane Device That Modulates the Excessive Inflammatory Response to Sepsis.

Feng Ding,Joon Ho Song,Ju Young Jung,Liandi Lou,Min Wang,Linda Charles,Angela Westover,Peter L. Smith,Christopher J. Pino,Deborah A. Buffington,H. David Humes

DOI: https://doi.org/10.1371/journal.pone.0018584

IF: 3.7

2011-01-01

PLoS ONE

Abstract:Objective Septic shock has a clinical mortality rate approaching fifty percent. The major clinical manifestations of sepsis are due to the dysregulation of the host's response to infection rather than the direct consequences of the invading pathogen. Central to this initial immunologic response is the activation of leukocytes and microvascular endothelium resulting in cardiovascular instability, lung injury and renal dysfunction. Due to the primary role of leukocyte activation in the sepsis syndrome, a synthetic biomimetic membrane, called a selective cytopheretic device (SCD), was developed to bind activated leukocytes. The incorporation of the SCD along an extracorporeal blood circuit coupled with regional anticoagulation with citrate to lower blood ionized calcium was devised to modulate leukocyte activation in sepsis. Design Laboratory investigation. Setting University of Michigan Medical School. Subjects Pigs weighing 30-35 kg. Interventions To assess the effect of the SCD in septic shock, pigs were administered 30×1010 bacteria/kg body weight of Escherichia coli into the peritoneal cavity and within 1 hr were immediately placed in an extracorporeal circuit containing SCD. Measurements and Main Results In this animal model, the SCD with citrate compared to control groups without the SCD or with heparin anticoagulation ameliorated the cardiovascular instability and lung sequestration of activated leukocytes, reduced renal dysfunction and improved survival time compared to various control groups. This effect was associated with minimal elevations of systemic circulating neutrophil activation. Conclusions These preclinical studies along with two favorable exploratory clinical trials form the basis of an FDA-approved investigational device exemption for a pivotal multicenter, randomized control trial currently underway.

Shock Synopsis July 2024

Shock Synopsis December 2024

Shock Synopsis April 2024

Shock Synopsis June 2024

The Clinical Efficacy of Intravenous IgM-enriched Immunoglobulin (pentaglobin) in Sepsis or Septic Shock: a Meta-Analysis with Trial Sequential Analysis

Comprehensive Therapeutic Efficacy Analysis of Intravenous Immunoglobulin in Treating Sepsis-induced Coagulopathy: A Single-Center, Retrospective Observational Study

Recombinant Human Activated Protein C for the Treatment of Severe Sepsis and Septic Shock: a Study Protocol for Incorporating Observational Evidence Using a Bayesian Approach.

Dosing of Extracorporeal Cytokine Removal In Septic Shock (DECRISS): protocol of a prospective, randomised, adaptive, multicentre clinical trial

Efficacy and safety of corticosteroids for septic shock in immunocompromised patients: A cohort study from MIMIC

Immunometabolic Chaos in Septic Shock

Intravenous Immunoglobulin G Therapy in Streptococcal Toxic Shock Syndrome: A European Randomized, Double-Blind, Placebo-Controlled Trial

Shock Synopsis March 2024

What's New in Shock, May 2019?

High-dose intravenous immunoglobulin versus albumin 4% in paediatric toxic shock syndrome: a randomised controlled feasibility study

Cellular Immunotherapy for Septic Shock. A Phase I Clinical Trial

Protocol for a pilot randomized controlled trial comparing plasma with balanced crystalloid resuscitation in surgical and trauma patients with septic shock

Shadows and lights in sepsis immunotherapy

The Effect of Sepsis and Septic Shock on the Viscoelastic Properties of Clot Quality and Mass Using Thromboelastometry: A Prospective Observational Study

Evaluation of the Efficacy and Safety of Intravenous Immunoglobulin (IVIG) in Moderate-to-Severe Hospitalized COVID-19 Patients: A Randomized, Open-Label Parallel-Group Study

Characterization of Early Peripheral Immune Responses in Patients with Sepsis and Septic Shock

A Biomimetic Membrane Device That Modulates the Excessive Inflammatory Response to Sepsis.